Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV

Inflammation associated with increased risk of comorbidities persists in people living with HIV (PWH) on combination antiretroviral therapy (ART). A recent placebo-controlled trial of low-dose methotrexate (MTX) in PWH found that numbers of total CD4 and CD8 T cells decreased in the low-dose MTX arm. In this report we analyzed T cell phenotypes and additional plasma inflammatory indices in samples from the trial. We found that cycling (Ki67+) T cells lacking Bcl-2 were reduced by MTX but plasma inflammatory cytokines were largely unaffected. In a series of in vitro experiments to further investigate the mechanisms of MTX activity, we found that MTX did not inhibit effector cytokine production but inhibited T cell proliferation downstream of mTOR activation, mitochondrial function, and cell cycle entry. This inhibitory effect was reversible with folinic acid, suggesting low-dose MTX exerts anti-inflammatory effects in vivo in PWH largely by blocking T cell proliferation via dihydrofolate reductase inhibition, yet daily administration of folic acid did not rescue this effect in trial participants. Our findings identify the main mechanism of action of this widely used anti-inflammatory medicine in PWH and may provide insight into how MTX works in the setting of other inflammatory conditions.

[1]  R. Siliciano,et al.  Antigen-driven clonal selection shapes the persistence of HIV-1 infected CD4+ T cells in vivo , 2020, bioRxiv.

[2]  M. Lederman,et al.  CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis , 2020, PLoS pathogens.

[3]  M. Lederman,et al.  "Inflammescent" CX3CR1+CD57+ CD8 T cells are generated and expanded by IL-15. , 2020, JCI insight.

[4]  T. Aune,et al.  Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[5]  C. Kovacs,et al.  BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo. , 2020, The Journal of clinical investigation.

[6]  P. Palma,et al.  Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART , 2019, Viruses.

[7]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[8]  M. Lederman,et al.  CD8+ T-Cell-Derived Tumor Necrosis Factor Can Induce Tissue Factor Expression on Monocytes. , 2019, The Journal of infectious diseases.

[9]  M. Lederman,et al.  Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  P. Ridker,et al.  Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate: AIDS Clinical Trials Group Study A5314 , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Shengyun Liu,et al.  Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis , 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[12]  J. Asara,et al.  The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. , 2017, Cell reports.

[13]  Daniel I. S. Rosenbloom,et al.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics , 2017, The Journal of experimental medicine.

[14]  M. Lederman,et al.  IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. , 2016, The Journal of clinical investigation.

[15]  J. Kremer,et al.  Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures , 2016, RMD Open.

[16]  M. Osiri,et al.  Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics , 2016, Clinical Rheumatology.

[17]  M. Lederman,et al.  SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction. , 2016, The Journal of infectious diseases.

[18]  D. O'Brien,et al.  Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size , 2016, Journal of Virology.

[19]  L. Hancox,et al.  Inflammatory IL-15 is required for optimal memory T cell responses. , 2015, The Journal of clinical investigation.

[20]  Stephen Brown,et al.  Methotrexate Is a JAK/STAT Pathway Inhibitor , 2015, PloS one.

[21]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[22]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[23]  M. Lederman,et al.  Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. , 2014, The Journal of infectious diseases.

[24]  P. Tugwell,et al.  Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis , 2014, The Journal of Rheumatology.

[25]  S. Deeks,et al.  Immunologic basis of cardiovascular disease in HIV-infected adults. , 2012, The Journal of infectious diseases.

[26]  J. Aviña-Zubieta,et al.  Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies , 2012, Annals of the rheumatic diseases.

[27]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[28]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[29]  J. Olesen,et al.  Extended Report , 2022 .

[30]  B. Cronstein,et al.  Methotrexate—how does it really work? , 2010, Nature Reviews Rheumatology.

[31]  S. Prey,et al.  Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: a systematic review , 2009, The British journal of dermatology.

[32]  P. van Riel,et al.  Methotrexate modulates the kinetics of adenosine in humans in vivo , 2005, Annals of the rheumatic diseases.

[33]  B. Ludviksson,et al.  The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. , 2005, Clinical immunology.

[34]  G. Alarcón,et al.  The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[35]  F. Breedveld,et al.  Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[36]  J. Marvel,et al.  Control of proliferation by Bcl-2 family members. , 2004, Biochimica et biophysica acta.

[37]  A. Gerards,et al.  UvA-DARE ( Digital Academic Repository ) Inhibition of cytokine production by methotrexate . Studies in healthy volunteers and patients with rheumatoid arthritis , 2007 .

[38]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[39]  Andreas Radbruch,et al.  Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4 , 2000, Annals of the rheumatic diseases.

[40]  P. Tugwell,et al.  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. , 2000, The Cochrane database of systematic reviews.

[41]  L. Genestier,et al.  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. , 1998, The Journal of clinical investigation.

[42]  J. Esdaile,et al.  Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. , 1993, Arthritis and rheumatism.

[43]  M. Weinblatt,et al.  Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. , 1993, The Journal of rheumatology.

[44]  I. Böhm,et al.  Mechanism of Action of Methotrexate: Experimental Evidence that Methotrexate Blocks the Binding of Interleukin 1β to the Interleukin 1 Receptor on Target Cells , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[45]  D. M. Hoffman,et al.  Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. , 1991, Annals of the rheumatic diseases.